Diagnosis and Treatment of Monkeypox Patients a Review

Salwa Hamza Hussein; Zainab Abd al-azim Dakil; Batheena  Abed alhassan Nasser

doi:10.17605/cajmns.v6i1.2705

Salwa Hamza Hussein Department of Biology, College of Education for Girls, Kufa University, Kufa, Iraq
Zainab Abd al-azim Dakil Department of Biology, College of Education for Girls, Kufa University, Kufa, Iraq
Batheena Abed alhassan Nasser Department of Biology, College of Education for Girls, Kufa University, Kufa, Iraq

DOI: https://doi.org/10.17605/cajmns.v6i1.2705

Keywords: Mpox, Health problem, Infection, Diagnosis and treatment

Abstract

A viral disease that affects children and young adults, it begins gradually and the infection may be mild. The infection turns into an acute stage in a high percentage of patients. The disease develops in the acute stage to encephalitis, myocarditis or pneumonia, and eye problems in severe cases.Monkeypox virus infection is a major public health problem worldwide. The country bears the largest burden in the world in terms of monkeypox infection and will be a major contributor to the elimination of this disease globally. The country has made good progress in reducing monkeypox virus infection in previous years, Iraq still faces challenges in achieving its goal of reducing the mortality and morbidity rate of monkeypox at present. Based on the objectives of the WHO global health sector strategy on monkeypox, we highlight other priorities for action to eliminate this virus in Iraq to achieve the impact goal of reducing mortality, and we suggest prioritizing service coverage targets for diagnosis and treatment. First, there is a need to improve the diagnostic and treatment capacities of medical institutions and health workers. Second, the government needs to reduce the financial burden of health care on patients. Third, there is a need for better coordination across existing national programs and resources to establish an integrated prevention and control system that covers prevention, screening, diagnosis and treatment of HIV infection and monkeypox across the life cycle. In this way, progress can be made towards the goal of eliminating monkeypox in Iraq.

References

R. Arbel, Y. Wolff Sagy, R. Zucker, N. Arieh, W. Wiessam, E. Battat, et al., "Effectiveness of a single-dose modified vaccinia Ankara in human monkeypox: an observational study," 2022.

A. W. Rimoin, P. M. Mulembakani, S. C. Johnston, J. O. Lloyd Smith, N. K. Kisalu, T. L. Kinkela, et al., "Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo," Proc. Natl. Acad. Sci. U. S. A., vol. 107, pp. 16262–16267, 2010, doi: 10.1073/pnas.1005769107.

T. Saito, T. Fujii, Y. Kanatani, M. Saijo, S. Morikawa, H. Yokote, et al., "Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8," JAMA, vol. 301, pp. 1025–1033, 2009, doi: 10.1001/jama.2009.289.

Y. Nishiyama, T. Fujii, Y. Kanatani, Y. Shinmura, H. Yokote, S. Hashizume, "Freeze-dried live attenuated smallpox vaccine prepared in cell culture 'LC16-KAKETSUKEN': Post-marketing surveillance study on safety and efficacy compliant with Good Clinical Practice," Vaccine, vol. 33, pp. 6120–6127, 2015, doi: 10.1016/j.vaccine.2015.09.067.

J. S. Kennedy, M. Gurwith, C. L. Dekker, S. E. Frey, K. M. Edwards, J. Kenner, et al., "Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults," J. Infect. Dis., vol. 204, pp. 1395–1402, 2011, doi: 10.1093/infdis/jir527.

P. R. Pittman, M. Hahn, H. S. Lee, C. Koca, N. Samy, D. Schmidt, et al., "Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox," N. Engl. J. Med., vol. 381, pp. 1897–1908, 2019, doi: 10.1056/NEJMoa1817307.

S. R. Walsh, M. B. Wilck, D. J. Dominguez, E. Zablowsky, S. Bajimaya, L. S. Gagne, et al., "Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial," J. Infect. Dis., vol. 207, pp. 1888–1897, 2013, doi: 10.1093/infdis/jit105.

E. T. Overton, S. J. Lawrence, J. T. Stapleton, H. Weidenthaler, D. Schmidt, B. Koenen, et al., "A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS," Vaccine, vol. 38, pp. 2600–2607, 2020, doi: 10.1016/j.vaccine.2020.01.058.

S. A. Sarkisian, et al., "A case series of smallpox vaccination-associated myopericarditis: effects on safety and readiness of the active-duty soldier," Mil. Med., vol. 184, no. 1–2, pp. e280–e283, 2019, doi: 10.1093/milmed/usy159.

C. Pugh, et al., "Povidone iodine ointment application to the vaccination site does not alter immunoglobulin G antibody response to smallpox vaccine," Viral Immunol., vol. 29, no. 6, pp. 361–366, 2016, doi: 10.1089/vim.2016.0025.

A. Berhanu, et al., "Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection," Antimicrob. Agents Chemother., vol. 59, no. 7, pp. 4296–4300, 2015, doi: 10.1128/AAC.00208-15.

A. M. Mandra, et al., "Myopericarditis associated with smallpox vaccination among US army personnel – Fort Hood, Texas, 2018," Disaster Med. Public Health Prep., 2021, doi: 10.1017/dmp.2020.478.

L. A. Jackson, et al., "Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: a randomized clinical non-inferiority trial," Vaccine, vol. 35, no. 13, pp. 1675–1682, 2017, doi: 10.1016/j.vaccine.2017.02.032.

J. S. Kennedy, "Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults," J. Infect. Dis., vol. 204, no. 9, pp. 1395–1402, 2011, doi: 10.1093/infdis/jir527.